Stifel downgraded Gracell (GRCL) to Hold from Buy with a price target of $10.25, down from $11, citing the acquisition of the company by AstraZeneca (AZN).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRCL:
- Gracell Biotechnologies Acquisition Completed
- Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
- Gracell announces shareholders’ approval of merger agreement
- Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
- Gracell announces FDA clearance of IND application for Phase 1 trial of GC012F